Renaissance Technologies LLC Purchases 45,554 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO)

Renaissance Technologies LLC grew its position in Xilio Therapeutics, Inc. (NASDAQ:XLOFree Report) by 18.3% in the second quarter, Holdings Channel.com reports. The fund owned 295,000 shares of the company’s stock after buying an additional 45,554 shares during the period. Renaissance Technologies LLC’s holdings in Xilio Therapeutics were worth $280,000 as of its most recent filing with the Securities and Exchange Commission.

Xilio Therapeutics Trading Up 1.6 %

Shares of XLO stock opened at $0.80 on Friday. The stock has a 50 day moving average of $0.82 and a two-hundred day moving average of $0.98. Xilio Therapeutics, Inc. has a 12 month low of $0.49 and a 12 month high of $2.89. The company has a market capitalization of $29.57 million, a P/E ratio of -0.31 and a beta of -0.10.

Xilio Therapeutics (NASDAQ:XLOGet Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). The business had revenue of $2.36 million during the quarter, compared to the consensus estimate of $30.00 million. Sell-side analysts predict that Xilio Therapeutics, Inc. will post -1.26 earnings per share for the current fiscal year.

About Xilio Therapeutics

(Free Report)

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.

Read More

Want to see what other hedge funds are holding XLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xilio Therapeutics, Inc. (NASDAQ:XLOFree Report).

Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.